The Cancer Index · Feb 2026
A company profile focused on Cleancard’s at-home urine-based cancer detection platform and its screening use case.
Making cancer detection as easy as a pregnancy test
Company research
Public company, workplace, funding, and market signals
Overview
Cleancard (rebranded publicly as Numen) is a San Francisco-based biotechnology startup developing rapid at-home cancer screening tests. Its core product is a 30-minute urine-based diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers, starting with prostate, bladder, and ovarian cancers.
Primary product
Rapid at-home cancer screening tests from urine samples, delivered through a synthetic-biology + AI diagnostic platform.
Founded
2021
Headquarters
San Francisco, California, United States
Team size
11-50
Industry
Biotechnology
Sub-industry
At-home cancer diagnostics / cancer screening
Offices
350 Parnassus Ave, Suite 300, San Francisco, CA 94117
Open Positions
0 jobs at Cleancard
No open positions
Check back later for new openings